News
BCRX
4.210
-3.88%
-0.170
Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Ironwood Pharma (IRWD)
TipRanks · 2d ago
Weekly Report: what happened at BCRX last week (0415-0419)?
Weekly Report · 3d ago
FYBR, BCRX and SABR are among after hour movers
Seeking Alpha · 6d ago
BioCryst: Brazilian Health Regulatory Agency Approves ORLADEYO - Quick Facts
NASDAQ · 04/17 09:49
BIOCRYST ANNOUNCES APPROVAL OF ORLADEYO® (BEROTRALSTAT) BY THE BRAZILIAN HEALTH REGULATORY AGENCY
Reuters · 04/17 08:30
BUZZ-US health insurers rise on UnitedHealth's upbeat Q1 profit
Shares of U.S. Health insurers rise between 2% and 5% in premarket trading after UnitedHealth Group UNH.N reports upbeat Q1 results. UnitedHealth maintains 2024 forecast despite disruptions caused by February cyberattack. Humana, CVS Health and Cigna also rise on UnitedHealth's results.
Reuters · 04/16 12:25
Weekly Report: what happened at BCRX last week (0408-0412)?
Weekly Report · 04/15 09:03
RBC Capital Keeps Their Buy Rating on BioCryst (BCRX)
TipRanks · 04/14 06:36
Optimizing Investment Strategies: A Deep Dive into BioCryst’s Stock Performance
TipRanks · 04/10 10:55
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 04/09 03:00
Weekly Report: what happened at BCRX last week (0401-0405)?
Weekly Report · 04/08 09:03
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shift From Loss To Profit
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company posted a loss of US$227m for its most recent financial year. It is expected to become profitable in 2026. An average annual growth rate of 65% is expected for the company.
Simply Wall St · 04/03 11:33
Weekly Report: what happened at BCRX last week (0325-0329)?
Weekly Report · 04/01 09:03
Weekly Report: what happened at BCRX last week (0318-0322)?
Weekly Report · 03/25 09:03
Weekly Report: what happened at BCRX last week (0311-0315)?
Weekly Report · 03/18 09:03
Weekly Report: what happened at BCRX last week (0304-0308)?
Weekly Report · 03/11 09:03
Tracking Baker Brothers Portfolio - Q4 2023 Update
Seeking Alpha · 03/06 22:09
BioCryst Pharmaceuticals (NASDAQ:BCRX investor three-year losses grow to 54% as the stock sheds US$74m this past week
BioCryst Pharmaceuticals, Inc. Shareholders have had a rough ride in the last three years. The share price is down 54% in that time, and is down 6.1% in the past week. The company grew revenue at 56% per year over the past three years, but the share price has fallen 16%. We look at the business performance of the company to see if there are red flags.
Simply Wall St · 03/05 10:57
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. Granted three newly-hired employees stock options to purchase an aggregate of 16,050 shares of common stock. The options and RSUs were granted as of February 29, 2024, as inducements to each employee entering into employment with the company.
Barchart · 03/05 06:01
Weekly Report: what happened at BCRX last week (0226-0301)?
Weekly Report · 03/04 09:03
More
Webull provides a variety of real-time BCRX stock news. You can receive the latest news about Biocryst Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.